Severe acute respiratory syndrome coronavirus 2 (ID 622817) - BioProject

Format

Choose Destination

Accession: PRJNA622817 ID: 622817

Severe acute respiratory syndrome coronavirus 2

See Genome Information for Severe acute respiratory syndrome-related coronavirus

Navigate Up

Navigate Across

407 additional projects are related by organism.

961 additional projects are components of the INSDC SARS-CoV-2 Viral Sequencing Data.

SARS-CoV-2 isolates generated at CDC

Accession	PRJNA622817
Data Type	Raw sequence reads, Genome sequencing
Scope	Multiisolate
Organism	Severe acute respiratory syndrome coronavirus 2[Taxonomy ID: 2697049] Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes; Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae; Betacoronavirus; Sarbecovirus; Severe acute respiratory syndrome-related coronavirus; Severe acute respiratory syndrome coronavirus 2
Publications	Harcourt J et al., "Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States.", Emerg Infect Dis, 2020 Jun;26(6):1266-1273
Submission	Registration date: 2-Apr-2020 CDC Pathogen Discovery Team
Relevance	Emerging pathogen
Locus Tag Prefix	HER16

Project Data:

Parameter	Value
Data volume, Gbases	18
Data volume, Mbytes	10328

Supplemental Content

Severe acute respiratory syndrome coronavirus 2
Severe acute respiratory syndrome coronavirus 2
Severe acute respiratory syndrome coronavirus 2 Raw sequence reads

BioProject
Severe acute respiratory syndrome coronavirus 2 strain:Gamma
Severe acute respiratory syndrome coronavirus 2 strain:Gamma
Severe acute respiratory syndrome coronavirus 2 strain:Gamma Raw sequence reads

BioProject
SARS-CoV-2 point mutation and deletion spectra, and their association with diffe...
SARS-CoV-2 point mutation and deletion spectra, and their association with different disease outcome
The study shows that mutant spectra of SARS-CoV-2 from diagnostic samples differed in point mutation abundance and complexity, and that significantly larger values were recorded in virus from patients who developed mild COVID-19 symptoms. The abundance of low frequency mutations marks a difference with other RNA viruses, and it may slow down the response of SARS-CoV-2 to escape specific selective constraints such as drugs or antibodies.

BioProject
undefined
undefined
A comparison of high-throughput SARS-CoV-2 sequencing methods using COVID-19 patient samples

BioProject

Your browsing activity is empty.

Activity recording is turned off.